Cancer pain remedy wins orphan drug status.
D001812:Blood-Brain Barrier; D003248:Constipation / Q000139:chemically induced / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D009020:Morphine / Q000494:pharmacology*; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000150:complications*; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D000644:Quaternary Ammonium Compounds; D014481:United States; D014486:United States Food and Drug Administration
D009292:Narcotic Antagonists; D000644:Quaternary Ammonium Compounds; C032257:methylnaltrexone; D009271:Naltrexone; D009020:Morphine